Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Sixfold Bioscience
AddedMar 22, 2024
UpdatedJul 7, 2026
Sixfold Bioscience

Sixfold Bioscience

Seed

Sixfold Bioscience: Pioneering RNA therapy delivery with patented systems.

HQ
London, Greater London, GB
Founded
2018
Accelerator
Y Combinator logoY CombinatorW18
Overview
Compare
Fundraising
Employees
Website

Sixfold Bioscience, founded with the mission to revolutionize RNA therapeutics, focuses on the commercialization of its patented drug delivery systems. These systems are designed to enhance the delivery of RNA-based therapies, including siRNAs for gene silencing and mRNAs for gene expression. The company's vision is to enable precise and effective treatments for a range of genetic disorders, positioning itself at the forefront of the RNA therapy market.

Notable figures associated with Sixfold Bioscience include its founders and key investors who have supported its innovative approach. The company has achieved significant milestones in developing and patenting its delivery systems, which have garnered attention within the biotech industry. Sixfold's impact is marked by its potential to transform therapeutic approaches to genetic diseases, offering new hope for patients through advanced RNA delivery technologies.

Sixfold Bioscience - Similar Companies

Ochre Bio logo

Ochre Bio

ochre-bio.com

Silence Therapeutics logo

Silence Therapeutics

64x Bio logo

64x Bio

64xbio.com

Locanabio logo

Locanabio

Engage Bio logo

Engage Bio

Nano RED logo

Nano RED

Wayfinder Biosciences logo

Wayfinder Biosciences

wayfinderbio.com

Excepgen logo

Excepgen

excepgen.com

Silvec Biologics logo

Silvec Biologics

silvec.com

Nuntius Therapeutics logo

Nuntius Therapeutics

nuntiustx.com

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

ParcelBio logo

ParcelBio

parcelbio.com

Traversa Therapeutics logo

Traversa Therapeutics

traversathera.com

ReNAgade Therapeutics logo

ReNAgade Therapeutics

Optimeos Life Sciences logo

Optimeos Life Sciences

optimeos.com

Sixfold Bioscience - Quick Facts

Who are Sixfold Bioscience's competitors?

Companies similar to Sixfold Bioscience include Ochre Bio, Silence Therapeutics, 64x Bio and Locanabio.

When was Sixfold Bioscience founded?

Sixfold Bioscience was founded in 2018.

Where is Sixfold Bioscience's headquarters located?

Sixfold Bioscience's headquarters is located in London, Greater London, GB.

When was Sixfold Bioscience's last funding round?

Sixfold Bioscience's most recent funding round was for $2.2M (USD) in December 2021.

How much has Sixfold Bioscience raised to-date?

As of Dec 2, 2021, Sixfold Bioscience has raised a total of $10.6M (USD).

How many employees does Sixfold Bioscience have?

Sixfold Bioscience has 33 employees as of Feb 24, 2024.

Sixfold Bioscience - Classification

NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software